Literature DB >> 22706838

Hemorrhagic complications associated with aspirin: an underestimated hazard in clinical practice?

Jolanta M Siller-Matula.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22706838     DOI： 10.1001/jama.2012.6152

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  7 in total

Review 1.  Aspirin and clopidogrel for prevention of ischemic stroke.

Authors:  Ruth M Thomson; David C Anderson
Journal:  Curr Neurol Neurosci Rep       Date:  2013-02       Impact factor: 5.081

2.  Do clinicians recommend aspirin to patients for primary prevention of cardiovascular disease?

Authors:  Kevin Fiscella; Paul C Winters; Michael Mendoza; Gary J Noronha; Carlos M Swanger; John D Bisognano; Robert J Fortuna
Journal:  J Gen Intern Med       Date:  2015-02       Impact factor: 5.128

3.  A short-term risk-benefit analysis of occasional and regular use of low-dose aspirin in primary prevention of vascular diseases: a nationwide population-based study.

Authors:  I-Chen Wu; Hui-Min Hsieh; Ming-Tsang Wu
Journal:  BMJ Open       Date:  2015-01-09       Impact factor: 2.692

4.  Aspirin treatment and risk of first incident cardiovascular diseases in patients with type 2 diabetes: an observational study from the Swedish National Diabetes Register.

Authors:  Nils Ekström; Jan Cederholm; Björn Zethelius; Björn Eliasson; Eva Fhärm; Olov Rolandsson; Mervete Miftaraj; Ann-Marie Svensson; Soffia Gudbjörnsdottir
Journal:  BMJ Open       Date:  2013-04-20       Impact factor: 2.692

5.  Interplay between genetic and clinical variables affecting platelet reactivity and cardiac adverse events in patients undergoing percutaneous coronary intervention.

Authors:  Jolanta M Siller-Matula; Irene M Lang; Thomas Neunteufl; Marek Kozinski; Gerald Maurer; Katarzyna Linkowska; Tomasz Grzybowski; Jacek Kubica; Bernd Jilma
Journal:  PLoS One       Date:  2014-07-22       Impact factor: 3.240

6.  A short-term effect of low-dose aspirin on major hemorrhagic risks in primary prevention: a case-crossover design.

Authors:  I-Chen Wu; Ming-Yen Lin; Fang-Jung Yu; Hui-Min Hsieh; Kuei-Fen Chiu; Ming-Tsang Wu
Journal:  PLoS One       Date:  2014-05-30       Impact factor: 3.240

7.  Aspirin for primary prevention of cardiovascular disease: a meta-analysis with a particular focus on subgroups.

Authors:  Georg Gelbenegger; Marek Postula; Ladislav Pecen; Sigrun Halvorsen; Maciej Lesiak; Christian Schoergenhofer; Bernd Jilma; Christian Hengstenberg; Jolanta M Siller-Matula
Journal:  BMC Med       Date:  2019-11-04       Impact factor: 8.775
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.